---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-105746"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2023-04-19T23:59:59+00:00"
generated_at: "2026-06-16T23:31:07.638021+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology reports Phase 1 data for ziftomenib: 30% CR, 35% CRc in R/R NPM1-m AML at RP2D

## Summary
- In 20 NPM1-m R/R AML patients at 600mg RP2D: CR rate 30%, composite CR (CRc) 35%, ORR 40%.
- Median duration of CRc response 8.2 months; median OS 5.1 months with 8.0 months follow-up.
- Safety: 85% had Grade ≥3 TEAEs; differentiation syndrome (any grade) 20%, Grade 3 DS 5%.
- Patients heavily pretreated: median 2.5 prior therapies, 60% prior venetoclax, 15% prior SCT.
- Registration-directed Phase 2 study of ziftomenib monotherapy in R/R NPM1-m AML now accruing.

## SEC filing metadata
- accession: 0001193125-23-105746
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2023-04-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312523105746/0001193125-23-105746-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312523105746/d467874d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-105746
- JSON: https://secwatch.observer/filing/0001193125-23-105746.json
- Plain text: https://secwatch.observer/filing/0001193125-23-105746.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.